The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Ventrus Receives Notice of Allowance for US Patent for VEN 307

01-Jun-2011 | Source : | Visits : 8340

NEW YORK - Ventrus Biosciences Inc. announced in a press release that the claims in its currently pending US Patent Application No. 09/355,928, titled "TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER" were found patentable by the US Patent and Trademark Office and a Notice of Allowance was posted on May 26, 2011.

"This is a significant milestone for our company, since this provides patent protection in the U.S. for the method of treatment, recited in the allowed claims, for the topical application of our product VEN 307 (2% diltiazem cream) for the treatment of anal fissures," said Dr. Russell H. Ellison, M.D., Chairman and CEO of Ventrus Biosciences Inc.

Upon payment of the required fee, the Letters Patent are expected to issue within a few months, the company said.

Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders.


Related Articles